Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




RF Device Detects Breast Cancer Margins During Surgery

By HospiMedica International staff writers
Posted on 12 Nov 2008
A novel detection system characterizes breast tissue during surgical procedure to determine the malignancy status of tumor margins throughout breast cancer surgery. More...


The Dune MarginProbe is an intraoperative, real-time, radiofrequency (RF) spectroscopy system that assists surgeons to positively detect tumor margins. The system is comprised of a sterile, disposable, hand-held probe and a portable console. When the probe tip is applied to an excised lumpectomy segment, RF signals are transmitted into the tissue and reflected back to the console, where they are analyzed using a specialized algorithm to determine tissue status. The system does not require any contrast agents or assistance from a radiologist or a pathologist. Each measurement performed by the MarginProbe scans a coin-shaped volume of tissue 7 mm wide by 1 mm deep. The streamlined operation and the ability to receive instantaneous results are designed to help with an easy integration into the existing surgical workflow. A recent study involving a 300-patient, prospective, randomized, controlled clinical trial of the MarginProbe compared surgeons' ability to detect and remove positive margins during an initial lumpectomy and the resulting reduced rate of repeat procedures. In the MarginProbe group, surgeons applied the probe to the excised lumpectomy specimen and shaved additional tissue according to the device's readings, resulting in a 56% reduction in repeat lumpectomies. The study was published in the October 2008 issue of The American Journal of Surgery.

The MarginProbe is a product of Dune Medical Devices (Caesarea, Israel), which has recently received an investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA). Dune will be launching a clinical trial of the MarginProbe in the United States, which will involve more than 600 women in over a dozen leading medical centers in New York City, Baltimore, Washington DC, Allentown, and Los Angeles.

"Based on the strength of our ongoing studies and their validation of the benefits of MarginProbe, we look forward to the device's acceptance within the surgical community,” said Dr. Dan Hashimshony, founder and CEO of Dune Medical Devices. "Soon thereafter, we hope to help ease the difficulties experienced by women who receive multiple surgeries for breast cancer.”

Related Links:

Dune Medical Devices


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.